OneDigital Investment Advisors LLC Acquires 6,511 Shares of Novo Nordisk A/S (NYSE:NVO)

OneDigital Investment Advisors LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 18.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 42,342 shares of the company's stock after buying an additional 6,511 shares during the period. OneDigital Investment Advisors LLC's holdings in Novo Nordisk A/S were worth $3,642,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Transce3nd LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $39,000. Finally, Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NVO shares. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Stock Performance

NVO stock traded down $0.56 during mid-day trading on Friday, reaching $62.07. 7,826,465 shares of the stock traded hands, compared to its average volume of 6,088,061. The firm has a market capitalization of $278.54 billion, a PE ratio of 18.87, a P/E/G ratio of 0.90 and a beta of 0.61. The business has a 50-day moving average of $74.03 and a two-hundred day moving average of $90.18. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is currently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.